Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/12/2025

Current Treatment for Gonorrhea

Uncomplicated Gonococcal Infections

  • The Centers for Disease Control and Prevention recommends ceftriaxone 250 mg IM as a single dose plus azithromycin 1g orally in a single dose as the first-line treatment regimen for uncomplicated gonorrhea 1, 2
  • Spectinomycin 2g IM in a single dose is a useful alternative for patients who cannot tolerate cephalosporins and quinolones 1, 3
  • Fluoroquinolones are no longer recommended due to widespread resistance 1, 2
  • Test of cure is not needed for uncomplicated infections treated with recommended regimens, but all sexual partners within 60 days should be evaluated and treated 4

Pharyngeal Gonococcal Infections

  • Pharyngeal infections are more difficult to eradicate than urogenital or rectal infections 5, 3
  • The recommended treatment for pharyngeal infections is ceftriaxone 250 mg IM in a single dose plus azithromycin 1g orally in a single dose 1, 3

Special Considerations

  • Surveillance for antimicrobial resistance is crucial for guiding therapy recommendations, and the Gonococcal Isolate Surveillance Project (GISP) monitors resistance patterns in the US 1
  • Clinicians should perform culture and susceptibility testing if treatment failure occurs 1
  • Treatment recommendations for HIV co-infected patients are the same as for HIV-negative patients 1

Common Pitfalls and Caveats

  • Failing to treat for potential chlamydial co-infection can lead to reinfection 1
  • Using fluoroquinolones despite high resistance rates can lead to treatment failure 1, 2
  • Not screening and treating sexual partners can lead to reinfection 4